Genflow Biosciences PLC Announces Holding in Company
Genflow Biosciences PLC (GENFF) has reported a change in company holdings through an acquisition or disposal of voting rights. The notification was submitted by Mr. Eric Leire on March 27, 2025, regarding a threshold crossing in shareholding that occurred on the same date. The disclosure was made in compliance with UK regulatory requirements and filed through the London Stock Exchange's news service (RNS).
The regulatory filing, completed in London, indicates a change in voting rights position, though specific details about the size and direction of the holding change were not disclosed in the announcement.
Genflow Biosciences PLC (GENFF) ha riportato una modifica nelle partecipazioni societarie attraverso un'acquisizione o una cessione dei diritti di voto. La notifica è stata presentata dal Sig. Eric Leire il 27 marzo 2025, riguardo a un superamento della soglia azionaria avvenuto nella stessa data. La comunicazione è stata effettuata in conformità con i requisiti normativi del Regno Unito ed è stata inviata tramite il servizio di notizie della Borsa di Londra (RNS).
Il deposito normativo, completato a Londra, indica un cambiamento nella posizione dei diritti di voto, sebbene i dettagli specifici sulla dimensione e la direzione della modifica della partecipazione non siano stati divulgati nell'annuncio.
Genflow Biosciences PLC (GENFF) ha informado sobre un cambio en las participaciones de la empresa a través de una adquisición o disposición de derechos de voto. La notificación fue presentada por el Sr. Eric Leire el 27 de marzo de 2025, respecto a un cruce de umbral en la tenencia de acciones que ocurrió en la misma fecha. La divulgación se realizó en cumplimiento con los requisitos regulatorios del Reino Unido y se presentó a través del servicio de noticias de la Bolsa de Londres (RNS).
El archivo regulatorio, completado en Londres, indica un cambio en la posición de derechos de voto, aunque no se divulgaron detalles específicos sobre el tamaño y la dirección del cambio en la tenencia en el anuncio.
Genflow Biosciences PLC (GENFF)는 의결권의 인수 또는 처분을 통해 회사의 보유 지분 변화를 보고했습니다. 이 통지는 에릭 레이르 씨에 의해 2025년 3월 27일에 제출되었으며, 같은 날짜에 발생한 지분 초과에 관한 것입니다. 이 공시는 영국의 규제 요건을 준수하며 런던 증권 거래소의 뉴스 서비스(RNS)를 통해 제출되었습니다.
런던에서 완료된 규제 서류는 의결권 위치의 변화를 나타내지만, 보유 변화의 크기와 방향에 대한 구체적인 세부 사항은 발표에 포함되지 않았습니다.
Genflow Biosciences PLC (GENFF) a signalé un changement dans les participations de l'entreprise par le biais d'une acquisition ou d'une cession de droits de vote. La notification a été soumise par M. Eric Leire le 27 mars 2025, concernant un franchissement de seuil dans la détention d'actions qui a eu lieu à la même date. La divulgation a été faite conformément aux exigences réglementaires du Royaume-Uni et déposée via le service d'actualités de la Bourse de Londres (RNS).
Le dépôt réglementaire, complété à Londres, indique un changement dans la position des droits de vote, bien que les détails spécifiques concernant la taille et la direction du changement de participation n'aient pas été divulgués dans l'annonce.
Genflow Biosciences PLC (GENFF) hat eine Änderung der Unternehmensbeteiligungen durch den Erwerb oder die Veräußertung von Stimmrechten gemeldet. Die Mitteilung wurde von Herrn Eric Leire am 27. März 2025 eingereicht, bezüglich eines Überschreitens der Schwelle im Aktienbesitz, das am selben Datum stattfand. Die Offenlegung erfolgte gemäß den regulatorischen Anforderungen des Vereinigten Königreichs und wurde über den Nachrichtenservice der London Stock Exchange (RNS) eingereicht.
Die regulatorische Einreichung, die in London abgeschlossen wurde, weist auf eine Änderung der Stimmrechtsposition hin, obwohl im Ankündigung keine spezifischen Details zur Größe und Richtung der Änderung des Anteils offengelegt wurden.
- None.
- None.
LONDON, UNITED KINGDOM / ACCESS Newswire / March 28, 2025 / 1. Issuer Details
ISIN
GB00BP2C3V08
Issuer Name
GENFLOW BIOSCIENCES PLC
UK or Non-UK Issuer
UK
2. Reason for Notification
An acquisition or disposal of voting rights
3. Details of person subject to the notification obligation
Name
MR ERIC LEIRE
City of registered office (if applicable)
15 Ingestre Place,
Country of registered office (if applicable)
UK
Name | City of registered office | Country of registered office |
Eric Leire |
|
|
4. Details of the shareholder
Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above
City of registered office (if applicable)
Country of registered office (if applicable)
5. Date on which the threshold was crossed or reached
27-Mar-2025
6. Date on which Issuer notified
27-Mar-2025
7. Total positions of person(s) subject to the notification obligation
| % of voting rights attached to shares (total of 8.A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer |
Resulting situation on the date on which threshold was crossed or reached | 36.180000 | 0.000000 | 36.180000 | 126514999 |
Position of previous notification (if applicable) | 35.600000 | 0.000000 | 35.600000 |
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
Class/Type of shares ISIN code(if possible) | Number of direct voting rights (DTR5.1) | Number of indirect voting rights (DTR5.2.1) | % of direct voting rights (DTR5.1) | % of indirect voting rights (DTR5.2.1) |
GB00BP2C3V08 | 126514999 |
| 36.180000 |
|
Sub Total 8.A | 126514999 | |||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
Type of financial instrument | Expiration date | Exercise/conversion period | Number of voting rights that may be acquired if the instrument is exercised/converted | % of voting rights |
|
|
|
|
|
Sub Total 8.B1 |
|
|
| |
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
Type of financial instrument | Expiration date | Exercise/conversion period | Physical or cash settlement | Number of voting rights | % of voting rights |
|
|
|
|
|
|
Sub Total 8.B2 |
|
|
| ||
9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
Ultimate controlling person | Name of controlled undertaking | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
|
|
|
|
|
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
12. Date of Completion
27-Mar-2025
13. Place Of Completion
London
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com .
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
When did Eric Leire report the change in Genflow Biosciences (GENFF) shareholding?
What type of transaction triggered the GENFF shareholding notification?
Where was the Genflow Biosciences (GENFF) shareholding notification filed?
What is the ISIN number for Genflow Biosciences (GENFF) stock?
